cysteamine has been researched along with micafungin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ishikawa, H; Jin, L; Kameyama, K; Kawachi, S; Kitagawa, Y; Kitajima, M; Kubota, T; Kumai, K; Nakamura, T; Saikawa, Y; Sano, K; Shinoda, M; Tanabe, M; Wada, N; Wakabayashi, G; Yoshida, M | 1 |
1 review(s) available for cysteamine and micafungin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cysteamine and micafungin
| Article | Year |
|---|---|
Intravenous injection of micafungin counteracts Candida albicans-induced aggravation of duodenal ulcers caused by cysteamine in rats.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Cysteamine; Duodenal Ulcer; Echinocandins; Injections, Intravenous; Lipopeptides; Lipoproteins; Male; Micafungin; Rats; Rats, Wistar; Severity of Illness Index; Treatment Outcome | 2008 |